Please assess the completion status of the following clinical trial:

Trial Title: Probiotic Lozenges for Treatment of Recurrent Aphthous Stomatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged 18-45 years old, 2. Patients presenting with RAS with the following characteristics: a. Minor aphthous ulcers less than 48 hours' duration prior to enrolment, b. Size no greater than 10 mm in diameter, c. A history that ulcers normally more than 5 days to resolve without treatment. The inclusion criteria for group B is the same except age, children with RAS aged between 3 and 12 years were recruited for the study.~Exclusion Criteria:~* A known history of hypersensitivities, immunologic or systemic diseases, pregnancy, smoking,~* treatment with systemic steroid or other immunomodulatory agents within 1 month before the study~* use of nonsteroidal anti-inflammatory drugs or oral antihistamines within 1 month prior to the study~* treatment of the ulcer with any preparation or medication within 72 hours prior to the study~* treatment with systemic antibiotics within 2 weeks prior to the study and a history of adverse reactions to lactose or fermented milk products.~* Children with a positive family history of RAS were excluded.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- ChocBalls (Type: EXPERIMENTAL): (L. acidophilus containing lozenges, PharmaCare Europe Ltd; West Sussex, RH10 9NQ, UK)
- Oracure oral gel (15 gm, Amun pharmaceutical company, Egypt) (Type: ACTIVE_COMPARATOR): Each 100 g contains:~Lidocaine HCI 2.0g. Cetylpyridinium chloride 0.1 g.

Based on this trial design, predict the completion outcome and termination type (if applicable).